Warning: The NCBI web site requires JavaScript to function. more...
Anti cancer effects of curcumin: cycle of life and death.
Sa G, Das T.
Cell Div. 2008 Oct 3;3:14.
Related citations
Final Report on Carcinogens Background Document for Formaldehyde.
National Toxicology Program.
Rep Carcinog Backgr Doc. 2010 Jan;(10-5981):i-512.
Multifocal signal modulation therapy of cancer: ancient weapon, modern targets.
Das T, Sa G, Saha B, Das K.
Mol Cell Biochem. 2010 Mar;336(1-2):85-95. Epub 2009 Oct 14. Review.
Cell cycle inhibition in malignant lymphoma: disease control by attacking the cellular proliferation machinery.
Ringshausen I, Peschel C, Decker T.
Curr Drug Targets. 2006 Oct;7(10):1349-59. Review.
Chemopreventive properties of curcumin.
Campbell FC, Collett GP.
Future Oncol. 2005 Jun;1(3):405-14.
Final Report on Carcinogens Background Document for Styrene.
Rep Carcinog Backgr Doc. 2008 Sep;(8-5978):i-398.
The targets of curcumin.
Zhou H, Beevers CS, Huang S.
Curr Drug Targets. 2011 Mar 1;12(3):332-47. Review.
Phytochemicals as cell cycle modulators--a less toxic approach in halting human cancers.
Singh RP, Dhanalakshmi S, Agarwal R.
Cell Cycle. 2002 May-Jun;1(3):156-61. Review.
Curcumin: The multi-targeted therapy for cancer regression.
Hossain DS, Bhattacharyya S, Das T, Sa G.
Front Biosci (Schol Ed). 2012 Jan 1;4:335-55.
Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma.
Wilken R, Veena MS, Wang MB, Srivatsan ES.
Mol Cancer. 2011 Feb 7;10:12. Review.
Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials.
Strimpakos AS, Sharma RA.
Antioxid Redox Signal. 2008 Mar;10(3):511-45. Review.
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M.
Adv Enzyme Regul. 2006;46:249-79. Epub 2006 Jul 18.
Chemopreventive potential of curcumin in prostate cancer.
Teiten MH, Gaascht F, Eifes S, Dicato M, Diederich M.
Genes Nutr. 2010 Mar;5(1):61-74. Epub 2009 Oct 6.
Induction of apoptosis by curcumin and its implications for cancer therapy.
Karunagaran D, Rashmi R, Kumar TR.
Curr Cancer Drug Targets. 2005 Mar;5(2):117-29. Review.
Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials.
Shehzad A, Wahid F, Lee YS.
Arch Pharm (Weinheim). 2010 Sep;343(9):489-99. Review.
Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells.
Reuter S, Eifes S, Dicato M, Aggarwal BB, Diederich M.
Biochem Pharmacol. 2008 Dec 1;76(11):1340-51. Epub 2008 Aug 3. Review.
Position statement. Part one: Immune function and exercise.
Walsh NP, Gleeson M, Shephard RJ, Gleeson M, Woods JA, Bishop NC, Fleshner M, Green C, Pedersen BK, Hoffman-Goetz L, Rogers CJ, Northoff H, Abbasi A, Simon P.
Exerc Immunol Rev. 2011;17:6-63. Review.
Chemopreventive agents alters global gene expression pattern: predicting their mode of action and targets.
Narayanan BA.
Curr Cancer Drug Targets. 2006 Dec;6(8):711-27. Review.
The anti-cancer efficacy of curcumin scrutinized through core signaling pathways in glioblastoma.
Su CC, Wang MJ, Chiu TL.
Int J Mol Med. 2010 Aug;26(2):217-24.
Novel aspects for the application of Curcumin in chemoprevention of various cancers.
Bachmeier BE, Killian P, Pfeffer U, Nerlich AG.
Front Biosci (Schol Ed). 2010 Jan 1;2:697-717. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on